CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Key Stats

• Today's Range: $54.08 to $55.27
• 50-Day Range: $43.19 to $68.14
• 52-Week Range: $30.04 to $71.13
• Volume: 317,072 shs
• Average Volume: 2.59 million shs
• Market Capitalization: $4.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.60
• Consensus Rating: Moderate Buy

CRISPR Therapeutics Stock Analysis - MarketRank™

CRISPR Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 270th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 9 buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CRISPR Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.16) to ($4.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CRISPR Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CRISPR Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CRISPR Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

26.94% of the float of CRISPR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in CRISPR Therapeutics has recently decreased by 7.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CRISPR Therapeutics does not currently pay a dividend.

Dividend Growth

CRISPR Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.94% of the float of CRISPR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in CRISPR Therapeutics has recently decreased by 7.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.98

News Sentiment

CRISPR Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for CRISPR Therapeutics this week, compared to 14 articles on an average week.

Search Interest

Only 49 people have searched for CRSP on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

MarketBeat Follows

Only 35 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -5% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, CRISPR Therapeutics insiders have bought 36,343.09% more of their company's stock than they have sold. Specifically, they have bought $51,499,918.00 in company stock and sold $141,316.00 in company stock.

Percentage Held by Insiders

Only 4.10% of the stock of CRISPR Therapeutics is held by insiders.

Percentage Held by Institutions

69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRSP Stock Analysis - Frequently Asked Questions

How have CRSP shares performed this year?

CRISPR Therapeutics' stock was trading at $39.36 at the beginning of the year. Since then, CRSP shares have increased by 37.5% and is now trading at $54.13.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Monday, August, 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics's revenue for the quarter was up 72.5% on a year-over-year basis.

When did CRISPR Therapeutics IPO?

CRISPR Therapeutics (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are CRISPR Therapeutics' major shareholders?

Top institutional shareholders of CRISPR Therapeutics include ARK Investment Management LLC (11.79%), State Street Corp (3.60%), Orbis Allan Gray Ltd (3.04%) and Sumitomo Mitsui Trust Group Inc. (2.80%). Insiders that own company stock include Simeon George, Samarth Kulkarni, James R Kasinger, Julianne Bruno, John Greene, Raju Prasad and Naimish Patel.
View institutional ownership trends.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 8/25/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRSP
• CIK: 1674416
• Web: www.crisprtx.com
• Phone: (141) 561-3277
• Fax: N/A
• Employees: 460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for CRISPR Therapeutics: $71.60
• High Price Target: $120.00
• Low Price Target: $32.00
• Potential Upside/Downside: +32.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$366.25 million
• Net Margins: -1,229.43%
• Pretax Margin: -1,218.98%
• Return on Equity: -20.05%
• Return on Assets: -17.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.61
• Quick Ratio: 16.61

Sales & Book Value

• Annual Sales: $37.31 million
• Price / Sales: 131.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.64 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 90,950,000
• Free Float: 87,221,000
• Market Cap: $4.92 billion
• Optionable: Optionable
• Beta: 1.80